Lilly Bio-Medicines president Ilya Yuffa is responsible for a portfolio of commercial products experiencing high sales growth rates, but with the exception of Taltz (ixekizumab), Eli Lilly and Company’s immunology, pain and neuroscience therapies are growing from a smaller base than the blockbuster drugs in the company’s established diabetes and burgeoning oncology portfolios.
Scrip spoke with Yuffa about Lilly’s plans for its Bio-Medicines portfolio to offset competition and reimbursement constraints for Taltz, Olumiant...